Publications by authors named "Sergio Schusterschitz S Araujo"
Article Synopsis
- This study tested pegcetacoplan, a targeted therapy aimed at treating these conditions, over 48 weeks in two patient groups with CAD and wAIHA who received either 270 or 360 mg/day.
- Results showed that pegcetacoplan was generally well tolerated with minimal serious side effects, and it effectively increased hemoglobin levels and reduced hemolysis in both groups.